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Systemic lupus erythematosus (SLE) is a chronic 
multiorgan autoimmune inflammatory disease 
that affects many organs and causes multiple pa-
thologies, including but not limited to glomeru-
lonephritis, arthritis, and skin lesions. SLE is 
characterized by a loss of tolerance to endogenous 
nuclear antigens, resulting in the production of 
autoantibodies that bind nuclear components, 
such as chromatin, double-stranded (ds) DNA, 
and ribonucleoproteins (RNP; Fairhurst et al., 
2006; Shlomchik, 2009; Theofilopoulos et al., 
2010). However, many studies indicate that dys-
regulation of innate immunity, particularly secre-
tion of IFN-, contributes to pathogenesis of 
SLE (Banchereau and Pascual, 2006; Marshak-
Rothstein and Rifkin, 2007; Gilliet et al., 2008; 
Guiducci et al., 2009; Santer et al., 2009; 
Theofilopoulos et al., 2010; Elkon and Santer, 
2012). SLE activity and autoantibody levels are 
associated with a marked IFN- signature in the 
blood and skin (Baechler et al., 2003; Bennett 
et al., 2003; Crow et al., 2003). Nonautoimmune 
patients treated with soluble IFN- can de-
velop a lupuslike syndrome and accumulation 
of autoantibodies (Båve et al., 2003; Santiago-
Raber et al., 2003). Viral infections, UV-mediated 
skin injury, or other events leading to IFN- 
production induce SLE flares. Mice strains that 
spontaneously develop a lupus-like disease have 
less severe disease when backcrossed to mice 
deficient for the receptor for IFN- (IFNAR; 
Santiago-Raber et al., 2003) or when treated 
with an antibody that blocks the IFNAR (Baccala 
et al., 2012). IFNAR-deficient mice are resistant 
to induction of experimental lupus (Nacionales 
et al., 2007).
Plasmacytoid DCs (pDCs) are bone marrow–
derived cells that specialize in the secretion 
of IFN-/ in response to viral infections 
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Plasmacytoid dendritic cells (pDCs) have long been implicated in the pathogenesis of lupus. 
However, this conclusion has been largely based on a correlative link between the copious 
production of IFN-/ by pDCs and the IFN-/ “signature” often seen in human lupus 
patients. The specific contribution of pDCs to disease in vivo has not been investigated in 
detail. For this reason, we generated a strain of BXSB lupus-prone mice in which pDCs can 
be selectively depleted in vivo. Early, transient ablation of pDCs before disease initiation 
resulted in reduced splenomegaly and lymphadenopathy, impaired expansion and activation 
of T and B cells, reduced antibodies against nuclear autoantigens and improved kidney 
pathology. Amelioration of pathology coincided with decreased transcription of IFN-/–
induced genes in tissues. PDC depletion had an immediate impact on the activation of 
immune cells, and importantly, the beneficial effects on pathology were sustained even 
though pDCs later recovered, indicating an early pDC contribution to disease. Together, our 
findings demonstrate a critical function for pDCs during the IFN-/–dependent initiation 
of autoimmune lupus and point to pDCs as an attractive therapeutic target for the treat-
ment of SLE.
© 2014 Rowland et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
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results in duplication and increased expression of TLR7 in 
male mice, which causes accelerated autoimmunity (Deane 
et al., 2007; Fairhurst et al., 2008).
Our analysis of pDC depletion in BXSB.DTR mice indi-
cates that pDCs are important for the initiation of lupus. We 
find reduced activation and expansion of immune cells, lim-
ited autoantibody production, and less severe glomerulo-
nephritis when pDCs are depleted during the early stage of 
disease; this general alleviation of pathology coincides with 
decreased transcription of IFN-stimulated genes (ISGs) after 
pDC ablation. Our data indicate that the pathogenic effects 
of pDCs are particularly important during the early phase of 
disease, as a transient depletion was sufficient to ameliorate 
disease in BXSB.DTR mice. PDCs, therefore, represent an 
attractive therapeutic target for the treatment of SLE.
RESULTS
Specific depletion of pDCs in lupus-prone BXSB.DTR mice
To evaluate the contribution of pDCs to the pathogenesis of 
lupus, we serially backcrossed the BDCA2-DTR transgene to 
lupus-prone BXSB/MpJ mice, generating BXSBxBDCA2-
DTR Tg mice (referred to throughout as BXSB.DTR mice). 
Lupus susceptibility loci on BXSB chromosome 1 were se-
lected for until homozygous for BXSB alleles using 4 SSLP 
markers adjacent to known lupus susceptibility loci: D1Mit 
231 (12cM), D1Mit156 (32.8 cM), D1Mit387 (62 cM), and 
D1Mit356 (95.8 cM; Haywood et al., 2006), and the BXSB Y 
chromosome was maintained during breeding. Our breed-
ing scheme produced BXSB littermates that expressed the 
DTR (BXSB.DTR+) and those that did not (BXSB.DTR–). 
BXSB.DTR– mice served as lupus control animals that did 
not respond to DT treatment and remained pDC sufficient 
for the duration of the experiments. Importantly, DT-treated 
BXSB.DTR– mice also served as controls for any potential 
toxicity related to the DT treatments. The results obtained 
from all PDC-sufficient cohorts (BXSB.DTR– mice treated 
with either DT or PBS and BXSB.DTR+ mice treated with 
PBS) were consistent among the groups with no significant dif-
ferences between the two treatments. Thus, as for BDCA2-DTR 
Tg mice, pDC depletion after repeated injections of DT was 
effective and well tolerated in autoimmune BXSB.DTR mice 
(Fig. 1 A and not depicted).
Transient pDC depletion results in persistently  
impaired T cell activation in BXSB.DTR mice
We sought to examine the effect of early pDC ablation on the 
progression of disease. Male BXSB.DTR+ mice were tran-
siently depleted of pDCs before the onset of clinical symp-
toms by twice-weekly injections of DT from 8 to 11 wk of 
age. PDC depletion was verified in a cohort of 11-wk-old 
mice after the final DT treatment. More than 95% ablation 
was achieved in the spleen, even after repeated injections of 
DT (Fig. 1 A). We found no effect on the pDC compartment 
when littermate control animals that did not express the DTR 
transgene (BXSB.DTR–) were treated with DT (Fig. 1 A). 
A cohort of control BXSB.DTR– and BXSB.DTR+ animals 
(Gilliet et al., 2008). PDCs detect viral nucleic acids and 
their synthetic analogues through TLR7 and TLR9, which 
are located in specialized endosomes (Barbalat et al., 2010; 
Theofilopoulos et al., 2010). These receptors trigger a MyD88-
dependent signaling pathway that leads to production of 
IFN-/, as well as IL-12, IL-6, and various other proin-
flammatory chemokines. Several studies have suggested that 
pDCs are also a major source of IFN- in SLE. PDCs infil-
trate the skin lesions of SLE patients (Farkas et al., 2001); they 
also secrete IFN- after Fc-receptor–mediated endocytosis of 
autoantibody–nucleic acid immune complexes and delivery 
of nucleic acids to the TLR7- and TLR9-containing endo-
somes (Dzionek et al., 2001; Båve et al., 2003; Barrat et al., 
2005; Means et al., 2005; Vollmer et al., 2005). pDCs also secrete 
IFN- in responses to neutrophils that die after exposure to 
SLE-derived antiribonucleoprotein antibodies. Dead neutro-
phils release neutrophil extracellular traps (NETs), which con-
tain endogenous DNA that enters pDC endocytic compartments 
after forming complexes with cationic proteins (Lande et al., 
2007; Tian et al., 2007; Garcia-Romo et al., 2011).
Although these studies indicate that pDC secretion of 
IFN- may contribute to the pathogenesis of SLE, the data 
linking pDCs to SLE are largely correlative and the specific 
role of pDCs in SLE pathogenesis has not been directly ad-
dressed. The study of pDCs in vivo has historically relied on 
the use of depleting monoclonal antibodies (Asselin-Paturel 
et al., 2001; Blasius et al., 2006). However, pDC-depleting 
mAbs are cross-reactive and eliminate many other cells in 
addition to pDC, yielding ambiguous phenotypes. To avoid 
these complications, we generated transgenic (tg) mice that 
express the diphtheria toxin receptor (DTR) under the con-
trol of the highly specific human pDC promoter, CLEC4C 
or BDCA2, in which administration of diphtheria toxin (DT) 
results in the selective systemic ablation of pDCs. More than 
95% of pDCs are depleted within 24 h after initial DT treat-
ment (Swiecki et al., 2010). Importantly, BDCA2-DTR tg 
mice tolerate repeated injections of DT with no detrimental 
effects, permitting long-term depletion of pDCs (Swiecki et al., 
2010). To evaluate the impact of pDCs in the pathogenesis of 
SLE, we backcrossed the BDCA2-DTR transgene onto the 
autoimmune-prone BXSB background. BXSB is a recombi-
nant inbred strain that recapitulates the proliferative glomeru-
lonephritis observed in human SLE. BXSB mice develop 
anti-nuclear autoantibodies (ANA), including anti-dsDNA, 
-ssDNA, -RNP, and -ssRNA, as well as splenomegaly and 
lymphadenopathy. Disease susceptibility in BXSB is linked 
to several genetic loci, particularly the telomeric region of 
chromosome 1, which encodes Fcr2b, Ifi202, and SLAM/
CD2 family members (Morel et al., 2001; Lauwerys and 
Wakeland, 2005; Fairhurst et al., 2006; Haywood et al., 2006; 
Theofilopoulos et al., 2010). Moreover, BXSB mice express 
the Y chromosome–linked autoimmune accelerator gene 
Yaa. The Yaa mutation arose from a translocation from the 
telomeric end of the X chromosome onto the Y chromo-
some, and contains the gene encoding TLR7 (Pisitkun et al., 
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population after pDC ablation. Importantly, pDC populations 
were equal in 19-wk-old BXSB.DTR male mice, irrespective 
of prior transient pDC depletion (Fig. 1 G). Moreover, pDCs 
in BXSB.DTR mice showed equivalent expression of CD86 
and MHC II regardless of earlier depletion (Fig. 1 H and not 
depicted), suggesting that a comparable level of activation 
was achieved by the recovered pDC population. This pDC 
activation is likely caused by the duplication of TLR7 in 
BXSB.DTR male mice, as pDCs from female BXSB.DTR 
mice displayed lower levels of CD86 expression (Fig. 1 H).
We also observed fewer activated CD4+ and CD8+ T cells 
in pDC-depleted BXSB.DTR mice relative to pDC-sufficient 
male littermates (Fig. 2 and not depicted). The population of 
cells identified as CD44highCD62Llow/– was reduced in both 
T cell subsets (Fig. 2, A and B). The reduced frequency of ac-
tivated CD44+ T cells correlated with an increase in the pop-
ulation of CD44–CD62L+ naive T cells (Fig. 2, A and C). In 
mice depleted of pDCs we also found fewer CD69+ CD8+  
T cells (Fig. 2 D). No differences in the frequency of regula-
tory T cells was detected at this time, and we did not observe 
any changes in the frequency or activation state of CD11c+ 
was treated concurrently with PBS (pDC-sufficient mice; not 
depicted). Depletion of pDCs was terminated when mice 
reached 11 wk of age and disease parameters were evaluated 
in 19-wk-old BXSB.DTR mice. After early pDC depletion, 
male BXSB.DTR mice had less marked splenomegaly and 
lymphadenopathy relative to male littermates that were pDC 
sufficient, and organ sizes were comparable to age-matched 
healthy female littermates (Fig. 1, B and C; and not depicted). 
The reduced cellularity was attributed primarily to a smaller 
number of T cells and, to a more variable extent, fewer B cells 
in the spleens of these mice. In particular, fewer CD4+ T cells 
were present after early pDC depletion (Fig. 1, D–F). We did 
not find a significant difference in the number of CD8+ T cells 
in pDC-depleted mice relative to male littermate controls 
(not depicted). However, parental male BXSB mice have been 
reported to have a diminished frequency of CD8+ T cells in 
comparison with age-matched female mice (Chu et al., 1994). 
Thus, although the overall number of CD8+ T cells is the 
same, this represents an increased frequency of CD8+ T cells in 
pDC-depleted mice relative to pDC-sufficient BXSB.DTR 
male mice and could be attributed to a rescue of the CD8+ T cell 
Figure 1. Reduced lymphoid organ hyperplasia in pDC-depleted BXSB.DTR mice. (A) Representative flow cytometric analysis of B220+SiglecH+ 
pDCs in spleen of 11-wk-old BXSB.DTR male littermates that were treated with DT as indicated. Female littermates were untreated (Untx). Spleen weight 
(B) and absolute spleen cell number (C) were determined in indicated mice. Number of CD19+ splenocytes (D), CD3+ splenocytes (E), and CD4+ splenic  
T cells (F) was determined by flow cytometry. (G) Frequency and absolute cell number of splenic pDCs and CD86 expression on splenic pDCs (H) was as-
sessed by flow cytometry and CD86 expression is represented as geometric MFI. In B–H, male DTR+ and DTR– mice were treated with DT and analyzed at 
19 wk of age. Untreated, healthy female littermates are shown. Data points indicate individual mice grouped from 10–11 experiments. Bar indicates arith-
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As reported for the BXSB/MpJ parental strain, pDC-sufficient 
BXSB.DTR control mice lost the CD23–CD21high MZ B cell 
compartment by 19 wk of age. However, this compartment was 
restored when pDCs were depleted early during disease (Fig. 3, 
A and B).
Another abnormal B cell feature of the BXSB/MpJ pa-
rental strain, and several other autoimmune strains, is the 
presence of an unusual population of age-associated B cells 
(ABCs), which is also present in the peripheral blood of some 
autoimmune women (Rubtsov et al., 2011) and tends to ac-
cumulate in elderly normal female mice (Hao et al., 2011; 
Rubtsov et al., 2011). ABCs reside within the CD23–CD21– 
double-negative (DN) B cell population, which also includes 
transitional-1 (T1) B cells. Although T1 B cells express AA4.1, 
ABCs are negative for AA4.1 and express CD11c and CD11b 
(Hao et al., 2011; Rubtsov et al., 2011). Early pDC depletion 
in BXSB.DTR male mice resulted in a reduction in the 
CD19+CD23–CD21– DN spleen B cell population. Within 
the DN population, we observed a trend toward a decrease 
in the frequency of DN cells with the ABC phenotype 
(AA4.1–) and an increase in the frequency of DN cells exhib-
iting a T1 phenotype (AA4.1+), suggesting that pDCs con-
tribute to the accumulation or expansion of ABCs (Fig. 3, 
A and C). Cells within the AA4.1– population expressed 
CD11c, consistent with their identification as ABCs (Hao 
et al., 2011; Rubtsov et al., 2011; and unpublished data). 
Remarkably, a subset of pDC-sufficient male BXSB.DTR 
mice developed a noticeable population of DN cells in the 
lymph nodes that were never observed in healthy animals 
(Fig. 3 D and not depicted). Healthy female controls and 
male BXSB.DTR mice that were depleted of pDCs did not 
harbor this population within the lymph nodes, again corrobo-
rating that pDCs may promote the aberrant expansion of ABCs 
in lymph nodes during lupus.
We observed subtle effects on the other B cell compart-
ments after pDC depletion. There was little change in the 
frequency of CD23highCD21low transitional 2 (T2)/follicular 
(Fo) B cells in the spleen. However, although not significant, 
the absolute number of T2/Fo B cells tended to be slightly 
lower in pDC-depleted mice (unpublished data). The popu-
lation of CD19low/–B220low/–CD138+ plasma cells remained 
relatively uniform among the mice (unpublished data). De-
spite little change in the frequencies of antibody-secreting 
cells, early pDC depletion resulted in reduced serum Ig 
relative to pDC-sufficient control animals. Circulating 
levels of IgG were reduced in the serum of pDC-depleted 
BXSB.DTR mice (Fig. 4 A). The overall prevalence of 
antinuclear autoantibodies (ANAs) was also reduced in 
DT treated BXSB.DTR+ mice relative to littermate control 
animals with an intact pDC compartment (Fig. 4 B). The de-
crease in serum immunoglobulin titers was not attributable 
to a single IgG isotype. Rather, IgM and all IgG subclasses 
were reduced in animals that were previously depleted of 
pDCs (Fig. 4, C and D). To determine which self-antigens 
were recognized, we performed a qualitative analysis to 
screen for autoantibody reactivity by autoantigen array. We 
or CD11b+ DC populations in the spleen, based on the 
level of MHC II and CD86 expression (unpublished data). 
We conclude that early transient pDC depletion persistently 
reduces T cell activation in BXSB.DTR mice.
Transient pDC depletion limits aberrant B cell  
development and generation of antinuclear  
autoantibodies in BXSB.DTR mice
It has been shown that male BXSB mice show features of abnor-
mal B cell development (Amano et al., 2003). One prominent 
feature is the loss of the marginal zone (MZ) B cell population. 
Figure 2. Transient pDC ablation impairs expansion and activa-
tion of T cells in BXSB.DTR mice. Male DTR+ and DTR– mice were 
treated with DT and analyzed at 19 wk of age. Untreated, healthy fe-
male littermates are shown. (A) Representative flow cytometric analysis 
of CD44 and CD62L expression on CD4+CD3+ splenocytes in the indi-
cated groups of mice. Frequency of CD44highCD62Llow (B), CD44low/–
CD62L+ (C), and CD69+ CD4+ and CD69+CD8+ (D) T cells in spleen of the 
indicated mice were determined by flow cytometry. Data points indicate 
individual mice grouped from 10–11 experiments. Bar indicates arith-
metic mean. *, P < 0.5; **, P < 0.01; ***, P < 0.001. Absence  
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regardless of prior pDC depletion (unpublished data). We 
conclude that transient pDC depletion ameliorates end-point 
kidney pathology.
Reduced IFN-/ gene signature in BXSB.DTR  
kidneys after transient pDC depletion
IFN-/–inducible genes are associated with the severity 
and progression of lupus (Baechler et al., 2003; Bennett et al., 
2003; Crow et al., 2003). We observed reduced local expres-
sion of several IFN-/ target genes, including mx1, oas3, 
irf 7, and ifit1, in kidney from pDC-depleted animals in com-
parison to kidney from pDC-sufficient mice (Fig. 6). In con-
trast, we found that the expression of IFN-/ gene targets 
in blood of 19-wk-old BXSB.DTR mice were unaffected by 
early pDC depletion (unpublished data). Together, these find-
ings suggest that early pDC ablation can lead to sustained re-
duction of local tissue IFN-/, inhibiting the initiation of 
the pathological progression of systemic lupus and eventual 
kidney damage in susceptible animals.
Transient pDC depletion has an immediate inhibitory  
effect on the activation and expansion of both innate  
and adaptive immune cells during the onset of lupus
To assess the immediate effects of pDC ablation we analyzed 
11-wk-old mice at the conclusion of DT treatments (Fig. 7 A). 
We observed that beneficial effects of pDC ablation were ap-
parent at this early time point. In 11-wk-old lupus-prone 
mice, we found a significant reduction in the organ weight 
and cellularity in the absence of pDCs (Fig. 7 B). As seen at 
later stages of disease, the reduced cellularity was primarily 
due to diminished CD4+ T cell and CD19+ B cell popula-
tions (Fig. 7 C). As seen in 19-wk-old animals, we observed 
an increased frequency of CD8+ T cells in pDC-depleted 
mice relative to pDC-sufficient BXSB.DTR male littermate 
mice, which rescued the population and resulted in equivalent 
overall numbers of these cells among the mice (unpublished 
observed a trend toward reduced antibody recognition of 
many lupus-associated antigens, including ssDNA, dsDNA, 
chromatin, and histones (Fig. 4, E and F), with recognition 
of Histone H2B the most reduced. However, not all lupus-
associated antigens evaluated were significantly reduced at 19 wk 
of age after early pDC depletion. We found little difference in 
the prevalence of La/SSB-, sm/RNP-, or U1-snRNP–specific 
autoantibodies at this time (Fig. 4, E and F). It is important 
to note that data obtained from the autoantigen arrays are 
not quantitative, but rather indicate the specificity of anti-
bodies present in the serum and relative autoantigen bind-
ing among lupusprone mice. Overall, these data demonstrate 
that transient pDC depletion limits aberrant B cell develop-
ment and autoantibody production.
Suppression of glomerulonephritis  
in pDC-depleted BXSB.DTR mice
Male BXSB mice develop proliferative glomerulonephritis and 
immune complex deposition in the kidney as disease pro-
gresses. Consistent with this, BXSB.DTR lupus control mice 
had high proteinuria and developed severe renal pathology 
(Fig. 5, A and B). Glomerular hypercellularity, as well as in-
creased mesangial matrix formation and thickening of glomeru-
lar membranes were evident in kidneys from pDC-sufficient 
control groups (Fig. 5, C and D). In contrast, BXSB.DTR 
mice subjected to early pDC ablation had less proteinuria and 
kidneys showed markedly less severe glomerular lesions, with 
limited cellular infiltrates and minimal matrix expansion or 
glomerular membrane thickening (Fig. 5, A–D). Moreover, 
IgG/C3 deposition in kidneys of BXSB.DTR mice was sig-
nificantly reduced in mice that were depleted of pDCs (Fig. 5, 
E and F). CD3+ T cells and CD11b+ myeloid cells were 
abundant in the kidney infiltrating leukocytes of pDC-sufficient 
mice but were significantly reduced after pDC ablation (Fig. 5, 
G–J). Gr1+ cells were seen in some control BXSB.DTR lit-
termates, but not found in any pDC-depleted animals (un-
published data). PDCs were not detected in any of the kidneys, 
Figure 3. Transient pDC depletion recon-
stitutes MZ B cells and inhibits the devel-
opment of ABCs. Male DTR+ and DTR– mice 
were treated with DT and analyzed at 19 wk 
of age. Untreated, healthy female littermates 
are shown. (A) Representative FACS analysis 
of CD23 and CD21 expression on CD19+ sple-
nocytes. Frequencies of CD23–CD21high MZ B 
cells (B) and CD23–CD21–AA4.1+ transitional-1 
B cells and CD23–CD21–AA4.1– ABCs (C) in 
spleen of indicated mice were determined by 
flow cytometry. Frequencies of CD23–CD21– 
CD19+ cells in lymph node (D) of indicated 
mice were determined by flow cytometry. 
Data points indicate individual mice grouped 
from 10–11 experiments. Bar indicates 
arithmetic mean. *, P < 0.5; **, P < 0.01;  











Published September 1, 2014
1982 pDCs in pathogenesis of lupus | Rowland et al.
reduction in the DC compartment; both CD11blow/–CD11chigh 
and CD11b+CD11chigh DC subset numbers were decreased 
after early ablation of pDCs (Fig. 7 H). Thus, the major hall-
marks of immune activation were less evident in mice imme-
diately after pDC depletion, which correlated with less severe 
end-point pathology in these animals.
data). We also observed reduced activation of CD4+ and 
CD8+ T cells, as measured by CD44, CD62L, and CD69 ex-
pression (Fig. 7, D–F). In addition, we found that the popula-
tion of B cells expressing the activation marker CD86 was 
reduced in the spleens of 11-wk-old pDC-depleted animals 
(Fig. 7 G). In 11-wk-old mice, there was also a significant 
Figure 4. Antinuclear antibodies are reduced in BXSB.DTR mice after transient pDC depletion. Male DTR+ and DTR– mice were treated with DT 
and analyzed at 19 wk of age. Untreated, healthy female littermates are shown. (A) Total IgG concentration in serum of indicated mice. (B) Antinuclear 
antibodies in sera were analyzed by HEp-2 assay. (left) Representative images are shown; (right) serum ANAs were titered to endpoint and Mann-Whitney 
test was applied. N.D. indicates signal was not detected at 1:40 dilution. (C) Concentration of IgG isotypes in serum of indicated mice was determined by 
ELISA. (D) Mean total serum immunoglobulin concentrations in indicated mice. (E) Sera from 19-wk-old male mice were subjected to an autoantigen 
microarray. Heat map of IgG antibody reactivity to indicated autoantigens in pDC-sufficient (BXSB.DTR–, DT) and pDC-depleted (BXSB.DTR+, DT) mice is 
shown. Each column represents an individual mouse; each row indicates a single antigen. Relative maximum row signals are shown in red; relative mini-
mum row signals are shown in blue. (F) Normalized signal of serum IgG reactivity for indicated antigens, as analyzed by autoantigen microarray described 
in (E). Data points indicate individual mice grouped from 10 experiments. Bar indicates arithmetic mean. *, P < 0.5; **, P < 0.01; ***, P < 0.001. Absence of 
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Analysis of IFN-/–stimulated genes in 11-wk-old 
mice indicated that the lupus-associated IFN-/ gene sig-
nature was markedly attenuated after early pDC depletion. 
Expression of IFN-/ gene targets was reduced in the pe-
ripheral blood of 11-wk-old pDC-depleted mice (Fig. 7 I). 
Together, these findings indicate an early role for IFN-/ 
in the initial expansion and activation of both innate and 
adaptive immune cells during the onset of lupus, which is 
likely mediated by the activity of pDCs.
Early, transient pDC depletion has an immediate  
inhibitory effect on autoantibody production
We analyzed the effect of early pDC ablation on the serum 
antibody profiles in 11-wk-old BXSB.DTR littermates at the 
conclusion of DT treatments. Similar to 19-wk-old animals, 
we observed a significant reduction in the abundance of cir-
culating IgG and IgM in the serum of pDC-depleted mice 
(Fig. 8, A and C). Again, serum immunoglobulins were re-
duced across all IgG subclasses (Fig. 8, B and C). As before, we 
performed a qualitative analysis to screen the specificities of 
serum antibodies by autoantigen array. We found a striking 
difference in the autoantibody repertoires of DT-treated 
BXSB.DTR– and BXSB.DTR+ animals analyzed at 11 wk of 
age. We observed reduced autoantibody reactivity to a wide 
variety of autoantigens, including many that are commonly 
associated with human lupus. Indeed, we found that antibody 
recognition of the lupus-associated antigens dsDNA, ssDNA, 
dsRNA, U1-snRNPs, La/SSB, chromatin, and histones were 
significantly reduced in the serum of mice that were previ-
ously depleted of pDCs (Fig. 8, D and E). Overall, these data 
indicate that transient pDC depletion limits, or delays, the 
early production of autoantibodies in lupus-prone mice.
Transient pDC depletion leads to reduced  
expression of lupus-associated soluble factors  
and inflammatory chemokines
We performed protein arrays to assess any changes in the ex-
pression of soluble factors that may mediate protection against 
the progression of lupus or indicate potential new biomarkers 
for disease. We screened sera samples from pDC-sufficient or 
pDC-depleted 11- and 19-wk-old BXSB.DTR mice using 
a multianalyte platform. Interestingly, we found less soluble 
VCAM-1 in pDC-deficient animals at both 11 and 19 wk of 
Figure 5. Early pDC depletion reduces severity of kidney pathology 
in BXSB.DTR mice. Male DTR+ and DTR– mice were treated with DT and 
analyzed at 19 wk of age. Untreated, healthy female littermates are 
shown. Proteinuria (A) and glomerulonephritis (B) were assessed in indi-
cated mice. Formalin-fixed kidney sections were stained with H&E (C) or 
PAS (D). Images are representative of four to eight animals per group. 
Frozen kidney sections were stained for IgG (E, red) and C3 (F, green) to 
identify immune complexes. Relative abundance of infiltrating CD3+ (G) 
and CD11b+ (H) cells in kidney of indicated mice were calculated. Images 
are representative of three animals per group. Frozen kidney sections 
were stained for (I) CD3 and (J) CD11b expression. Images are representa-
tive of three animals per group. Individual glomeruli are marked in histol-
ogy panels with the letter G. The magnification in C–F and I–J is 200×. 
Bars: (C, E, and I) 100 µm. Data points indicate individual mice from three 
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of innate and adaptive immune cells, as well as diminished 
end-point renal pathology and autoantibody production. 
Our data indicate an important role for pDCs during the 
onset of lupus, as early pDC depletion curbed activation of 
the host immune response in lupus-prone mice as young as 
11 wk of age. Importantly, the effects of transient, early pDC 
ablation were sustained and pathology was minimal at 19 wk 
of age, at which time the mice normally develop overt dis-
ease. Even though the population of pDCs returns to normal 
once treatment with DT is discontinued, the recovered pDCs 
appear to have minimal contributions to disease pathogene-
sis at later stages of disease, again illustrating an important role 
for pDCs in the early activation of other immune cells.
The early contribution of pDCs to lupus pathogenesis is 
likely mediated, at least in part, by the production of IFN-
/. We found a much less marked IFN-/–induced gene 
signature in the blood of young pDC-depleted mice, which 
correlated with reduced local gene expression in the tissues of 
older pDC-depleted mice. It was recently reported that chronic 
treatment of BXSB mice with an anti-IFNAR–blocking anti-
body improved clinical signs of lupus (Baccala et al., 2012), 
indicating an important role for IFN-/ in the pathogenesis 
of lupus. In this study, lupus symptoms were more effectively 
ameliorated when treatment with anti-IFNAR antibodies 
was initiated in younger BXSB mice rather than in older 
mice, after the onset of disease. The reduced efficacy of IFNAR 
blockade after disease onset, when activation of the adaptive 
immune response has already occurred, bolsters our view that 
pDCs and IFN-/ may play a less significant role in sustain-
ing pathogenesis at later stages of disease. However, our results 
do not exclude the potential effects of other inflammatory 
mediators produced by pDCs, such as IL-6, which was previ-
ously reported to facilitate plasma cell differentiation by act-
ing in combination with IFN-/ (Jego et al., 2003).
Our data suggest that pDCs control the early threshold 
activation of adaptive immune cells and accelerate the pro-
gression of lupus. CD4+ T cells are reportedly involved in the 
pathogenesis of lupus, potentially by providing signals for 
B cell activation. Indeed, an increased frequency of activated an-
tigen experienced CD44high CD4+ T cells has been reported in 
BXSB mice (Chu et al, 1994). We found fewer activated T cells 
age (Fig. 9 A). Soluble VCAM-1 is increased in human SLE pa-
tients relative to healthy controls and has been correlated with 
disease severity (Spronk et al., 1994; Ikeda et al., 1998; Howe 
et al., 2012). We also detected reduced soluble CD40L in the 
serum of pDC-depleted BXSB.DTR mice relative to pDC-
sufficient littermates (Fig. 9 B). Higher levels of soluble CD40L 
have also been reported in serum of SLE patients (Kato et al., 
1999; Vakkalanka et al., 1999; Goules et al., 2006), and may 
contribute to the activation of autoreactive B cells in lupus.
Although we saw no difference in the population of neu-
trophils in pDC-depleted BXSB.DTR mice relative to lupus-
controls (unpublished data), we found increased levels of 
circulating myeloperoxidase (MPO) in the serum of pDC-
sufficient lupus control animals (Fig. 9 C). Human lupus patients 
reportedly have higher levels of MPO in plasma compared 
with healthy controls (Telles et al., 2010). Thus, although 
neutrophil populations were similar between the groups, en-
hanced MPO production in pDC-sufficient BXSB.DTR– 
may indicate a difference in the activation status or function 
of these cells relative to pDC-depleted animals.
Additionally, we observed increased concentrations of the 
inflammatory chemokines MIP-1/CCL4, MIP-1/CCL9, 
and MCP-3/CCL7 in the serum of male pDC-sufficient 
BXSB.DTR mice relative to pDC-depleted littermates and 
healthy female controls (Fig. 9 D). Prior studies have noted 
that these proteins are expressed in human lupus patients and 
correlate with disease severity (Vilá et al., 2007; Bethunaickan 
et al., 2012; Santer et al., 2012). Thus, considered in the con-
text of previous studies, our findings support a role for pDCs 
in the induction of inflammatory chemokines during lupus.
DISCUSSION
Although pDCs were implicated in the pathogenesis of SLE 
some time ago, data supporting this conclusion are primarily 
correlative; the direct effects of pDCs on lupus have not been 
thoroughly investigated in vivo. In this study, we generated a 
novel mouse strain, BXSB.DTR, to selectively evaluate the 
contribution of pDCs to the progression of lupus in vivo. We 
find that the early, transient elimination of pDCs is sufficient 
to improve many of the clinical symptoms of lupus in the 
BXSB.DTR strain, including reduced expansion and activation 
Figure 6. Local expression of IFN-/–stimulated genes in kidney tissues is reduced after pDC depletion. Male DTR+ and DTR– mice were 
treated with DT and analyzed at 19 wk of age. Untreated, healthy female littermates are shown. Relative expression of indicated genes in kidney tissue 
was analyzed by RT-PCR. Data points indicate individual mice grouped from eight experiments. Bar indicates mean relative expression of indicated genes. 










Published September 1, 2014
JEM Vol. 211, No. 10 
Article
1985
further suggests that early activity of pDCs in BXSB mice 
promotes aberrant T cell activation and T cell trafficking to 
the kidneys. The study by Baccala et al. (2012) also reported a 
reduced frequency of CD4+ and CD8+ T cells expressing 
CD69 in BXSB mice undergoing chronic treatment with a 
expressing CD44 and CD69 in the spleens of BXSB mice 
that were subjected to early pDC depletion. We also noticed 
pDC-depleted mice had a remarkable reduction of kidney 
infiltrating CD3+ T cells, which reportedly promote nephritis 
in lupus-prone MRL/lpr mice (Okamoto et al., 2012). This 
Figure 7. Transient pDC depletion has an immediate effect on the activation and expansion of innate and adaptive immune cells. Male mice 
were treated with DT and analyzed at 11 wk of age. Untreated, healthy female littermates are shown. (A) Frequencies of B220+SiglecH+ pDCs 24 h after 
last DT treatment were determined by flow cytometry. (B) Spleen weight and absolute cell number were calculated in indicated mice. (C) Number of CD4+ 
and CD19+ splenocytes. Frequencies of CD44highCD62Llow (D), CD44low/–CD62L+ (E), and CD69+ CD4+ and CD69+CD8+ (F) T cells in spleen of indicated mice. 
(G) Frequencies of CD86+CD19+ splenocytes. (H) Number of CD11blow/–CD11chigh and CD11b+CD11chigh MHCII+ DCs in spleen of indicated mice. (I) Relative 
expression of indicated IFN-/–induced genes in peripheral blood was analyzed by RT-PCR. Data points indicate individual mice. Bar indicates arithmetic 
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in downstream adaptive immune system responses. For the 
MRL.Faslpr model of lupus, it has been reported that cDCs 
are important for the expansion and differentiation of T cells, 
however not for their initial activation (Teichmann et al., 
2010). Thus, we cannot dismiss that a direct effect of pDCs on 
T cells, or on other antigen-presenting cells, such as B cells, 
are important for the initial activation of T cells.
Several results indicate that pDCs may also have a crucial 
role in promoting abnormal B cell responses in lupus. We 
find that early pDC depletion results in the reappearance of 
MZ B cells, which are absent from BXSB mice with active 
signs of lupus (Amano et al., 2003). MZ B cells are thought 
of as innatelike B cells that function in the nonspecific, but 
rapid, defense against blood borne pathogens by secreting 
blocking antibody against IFNAR. Furthermore, we observed 
soluble CD40L in serum of 19-wk-old pDC-sufficient BXSB 
mice, which provides additional evidence of prior T cell acti-
vation. Soluble CD40L detected in sera of human SLE pa-
tients correlated with disease severity and may contribute to 
B cell activation (Kato et al., 1999; Vakkalanka et al., 1999; 
Goules et al., 2006). Together, these data suggest that T cell 
activation in the BXSB model is downstream of pDC–IFN-
/ axis. We have not determined whether the effects of 
pDCs on T cell responses are mediated directly by production 
of cytokines by pDCs or indirectly, perhaps by activation of 
intermediate cells such as conventional DCs (cDCs) or B cells. 
We found differences in cDC populations immediately after 
pDC depletion, which suggests that these cells may participate 
Figure 8. Transient pDC depletion has an immediate effect on the presence of circulating autoantibodies. Male DTR+ and DTR– mice were treated 
with DT and analyzed at 11 wk of age. Untreated, healthy female littermates are shown. (A–C) Total IgG concentration in serum (A), individual IgG isotypes 
(B), and mean total serum IgG concentration (C) was determined by ELISA in the indicated mice. (D) Sera from 11-wk-old male mice were subjected to an 
autoantigen microarray. Heat map of IgG antibody reactivity to indicated autoantigens in pDC-sufficient (BXSB.DTR–, DT) and pDC-depleted (BXSB.DTR+, DT) 
mice. Each column represents an individual mouse; each row indicates a single antigen. Relative maximum row signals are shown in red; relative minimum 
row signals are shown in blue. (E) Normalized signal of serum IgG reactivity for indicated antigens, as analyzed by autoantigen microarray described in (D). 
Serum autoantibodies (IgG) were analyzed by autoantigen microarray as in (D) and normalized signals for the indicated antigens are shown. Data points rep-
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serum of pDC-depleted mice, as quantified by HEp-2 assay. 
In complementary, qualitative array assays we found reduced 
antibody reactivity against several lupus-associated autoanti-
gens, primarily in 11-wk-old BXSB.DTR mice immediately 
after pDC depletion. These data suggest an immediate effect 
of pDC depletion on inhibiting, or delaying, the production 
of autoantibodies. By qualitative array assay, the differences 
in self-antigen recognition were less dramatic in 19-wk-old 
animals, with only reactivity to Histone H2B showing a sig-
nificant difference. The observation that this effect waned 
over time may indicate that pDCs are important for induc-
tion of disease, and in their absence the progression of lupus 
is delayed, but not completely abolished. However, it is im-
portant to note that the autoantigen arrays were performed 
using a single, standard serum dilution, which may not be 
optimal for all the samples given the differences in total serum 
Ig concentrations between pDC-sufficient and pDC-depleted 
animals. For this reason, it is possible that differences in antigen 
binding may be underestimated in the 19-wk-old animals, when 
overall serum Ig concentrations are higher relative to that seen 
in younger mice. Based on the serum concentrations and ANA 
titers, we conclude that transient pDC-depletion limits the 
production of autoantibodies in lupus-prone mice.
Additionally, we found evidence that pDC depletion re-
duced the expression of several soluble proteins that may be 
relevant to the progression of lupus. We observed lower lev-
els of soluble VCAM-1 (sVCAM-1) in BXSB.DTR mice 
that were previously depleted of pDCs. sVCAM-1 is found 
at higher levels in the serum and urine of human SLE patients 
relative to healthy controls and correlates with disease sever-
ity, including autoantibody production and incidence of lupus 
nephritis (Spronk et al., 1994; Ikeda et al., 1998; Howe et al., 
antibodies with broad reactivity (Cerutti et al., 2013). Al-
though the disappearance of MZ B cell compartment in 
BXSB mice is incompletely understood, it may indicate the 
differentiation of MZ B cells into autoantibody-secreting 
plasma cells. We also find that transient, early depletion of 
pDCs limited the development of ABCs, an unusual popula-
tion of B cells that were shown to accumulate with age in 
normal mice and were also found in young autoimmune 
prone animals as well as in patients with systemic autoimmu-
nity (Hao et al., 2011; Rubtsov et al., 2011). The accumula-
tion of these cells is dependent on TLR7 signaling (Hao et al., 
2011; Rubtsov et al., 2011). In addition, the ABC population 
is diminished after blockade of the IFNAR (Baccala et al., 
2012). These data suggest that the activity of pDCs early 
during the onset of autoimmunity promotes the dysregulated 
development of B cells into ABCs and this is likely due, at 
least in part, to the action of IFN-/ on B cells.
We did not detect any differences in the population of 
plasma cells in BXSB.DTR mice, regardless of early pDC 
depletion. Although there was no change in the CD138+ 
plasma cells, we did observe a reduction in total serum im-
munoglobulin titers and autoantibodies after pDC depletion. 
Serum immunoglobulins were reduced across all IgG iso-
types. BXSB.DTR mice that were depleted of pDCs had 
reduced autoantibodies against nuclear antigens. Thus, it is 
possible that although the frequency of plasma cells is un-
changed, there is a shift in the repertoire of antibodies that are 
produced in mice depleted of pDCs. It may be that the early 
production of IFN-/ by pDCs skews the B cell population 
toward having a more autoreactive BCR repertoire or affects 
the antibody production by these cells. Indeed, we found de-
creased overall titers of antinuclear autoantibodies (ANAs) in 
Figure 9. Reduced lupus-associated soluble factors and inflammatory chemokines in sera after early pDC depletion. Male DTR+ and DTR– mice were 
treated with DT and analyzed at 11 or 19 wk of age, as marked. Age-matched, untreated, healthy female littermates are included. Concentration of soluble  
(A) VCAM-1, (B) CD40L, (C) MPO, and (D) select chemokines in sera of indicated mice were determined by serum protein array. Data points indicate samples from 
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MATERIALS AND METHODS
Mice and treatments. BXSB/MpJ mice were obtained from The Jackson 
Laboratory. C57BL/6-Tg(CLEC4C-HBEGF)956Cln Tg mice (BDCA2-
DTR Tg mice) have been described (Swiecki et al., 2010). BXSBxBDCA2-
DTR mice were generated by breeding male BXSB/MpJ to female 
BDCA2-DTR mice, selecting for BXSB susceptibility loci on Chromosome 1 
during the initial backcrosses (Haywood et al., 2006). To distinguish them 
from the parental BxSB/MpJ strain, all mice from the line generated by 
backcrossing the BDCA2-DTR transgene to BXSB/MpJ will be referred to 
as BXSB.DTR mice (Tg+ BXSB.DTR+ and Tg BXSB.DTR– mice will 
only be distinguished when necessary). Female BXSB.DTR+ mice were 
bred to male BXSB/MpJ mice for all subsequent backcrosses, producing 
DT-responsive BXSB.DTR+ and DT-nonresponsive BXSB.DTR– litter-
mate mice for all experiments. Experimental mice were used at backcross 
generation N11-N14. Plasmacytoid DCs were depleted in BXSB.DTR+ 
mice by i.p. administration of 100 ng DT (Sigma-Aldrich) every 3–4 d for 
3 wk beginning when mice were 8 wk of age. PDC-sufficient control 
BXSB.DTR– littermates were injected with DT, and both BXSB.DTR+ and 
BXSB.DTR– mice were treated with PBS in parallel experiments (SLE con-
trols). Mice were housed under specific pathogen-free conditions and animal 
protocols were approved by the Animal Studies Committee at Washington 
University in Saint Louis.
Isolation of leukocytes. Whole blood was collected via cardiac puncture at 
time of sacrifice. Bone marrow cells were flushed with RPMI 1640 containing 
10% bovine calf serum (RPMI-10%). Spleens and lymph nodes were minced 
and digested with Collagenase D (Roche) for 45 min at 37°C in RPMI-10%. 
Spleen and lymph node tissues were pressed through nylon mesh strainers (BD) 
to yield single-cell suspensions. Red blood cells were removed from spleen and 
bone marrow with RBC lysis buffer (Sigma-Aldrich). Cells were counted by 
hemacytometer using Trypan Blue to exclude dead cells.
Flow cytometric analysis. Single-cell suspensions were stained with fluor-
escent monoclonal antibodies against B220 (RA3-6B2), CD3 (145.2c11), CD4 
(GK1.5 or RM4-5), CD8a (53–6.7), CD11b (M1/70), CD11c (N418), CD19 
(1D3), CD23 (B3B4), CD21/35 (7G6), CD93 (AA4.1), CD44 (IM7), CD62L 
(Mel14), CD86 (GL1), CD138 (281–2), FoxP3 (FJK-16a), Ki-67 (B56), 
SiglecH (551), CD69 (H1.2F3), IA/IE (2G9 or M5/114.14.2), purchased 
from BD, eBioscience, or BioLegend. Biotinylated antibodies were revealed 
with fluorochrome conjugated streptavidin (Invitrogen). Before staining, 
cells were treated for 10–15 min at room temperature with monoclonal anti-
body 197 (anti-mFcRI) to block Fc receptors, and dead cells were excluded 
during FACS analysis with addition of propidium iodide or 7AAD. Intracellu-
lar FoxP3 expression was analyzed according to manufacturer’s instructions 
(eBioscience) after surface marker staining. Staining for Ki67 expression was 
sometimes included with FoxP3 analysis. Data were acquired on a FACS-
Canto II (BD) and analyzed using FlowJo software (Tree Star, Inc.).
ELISAs. Sera were isolated from whole blood using serum collection 
tubes (BD) and stored at –20°C until use. Microtiter plates were coated 
overnight with 2 µg/ml goat anti–mouse IgG (Southern Biotech) diluted 
in PBS at 4°C. Plates were washed once (PBS, 0.1% Tween-20), blocked 
2 h at 37°C or 4°C overnight (PBS, 1% BSA), and again washed once. Sera 
were initially diluted 1:1,000 (IgG and IgM) or 1:500 (IgG isotypes), seri-
ally diluted threefold in blocking buffer, and incubated overnight at 4°C. 
Standard curves were generated using known concentrations of purified 
antibodies. Plates were washed three times and bound antibodies were de-
tected with horseradish peroxidase (HRP)-conjugated goat anti–mouse 
IgM, IgG, IgG2b, and IgG2c isotype-specific antibodies (1:500; Southern 
Biotech), HRP-goat anti–mouse IgG1 (1:1,000; Invitrogen) or HRP-
rabbit anti–mouse IgG3 (1:1,000; Rockland) for 1 h at 37°C. Plates were 
washed three times, and developed by adding peroxidase substrate buf-
fer comprised of 1 mg/ml o-phenylenediamine dihydrochloride (Sigma-
Aldrich) diluted in 0.05 M phosphate citrate buffer, pH 5.0. Absorbance 
values were read at 490 nm.
2012). Increased sVCAM-1 may indicate prior activation of en-
dothelial cells, perhaps as a result of immune complex deposi-
tion and complement activation, which could facilitate the 
migration of inflammatory cells into tissues.
We also observed that mice previously depleted of pDCs 
had reduced expression of the inflammatory chemokines 
MIP-1, MIP-1, and MCP-3. Interestingly, human lupus 
patients are reported to have higher serum concentrations of 
MIP-1 than healthy individuals, which correlate with tissue 
damage in SLE (Vilá et al., 2007). MIP-1 is found only in 
rodents (human orthologue MIP-1/CCL15), but lower 
levels of MIP-1 were found to correlate with less severe 
lupus nephritis in a murine model (Bethunaickan et al., 2012). 
Maximal induction of MCP-3 in response to immune com-
plexes from lupus serum was reported to be dependent on 
pDCs (Santer et al., 2012), a finding supported by the re-
duced expression of MCP-3 we noted after pDC depletion.
The role of pDCs in lupus in vivo has been indirectly 
studied using IRF8-deficient mice. It was concluded that 
pDCs are critical for the pathogenesis of lupus based on the 
limited production of autoantibodies against nuclear antigens 
(Baccala et al., 2013). In the same study, the phenotype of 
IRF8-deficient mice was similar to that of Slc15a4-deficient 
mice, which harbor pDCs that have impaired production of 
IFN-/ and inflammatory cytokines (Blasius et al., 2010). 
Although our data are in strong agreement that pDCs are im-
portant in lupus, our system represents an improved model 
for studying pDCs in vivo, as IRF8-deficient mice also have 
defects in CD8+ cDCs and IL-12 (Aliberti et al., 2003), 
whereas Slc15a4 is also expressed in B cells and therefore 
Slc15a4-deficient mice may have B cell intrinsic defects. As 
such, the nonspecific deletion of additional cell types may 
result in a more dramatic phenotype. Thus, although our data 
are in agreement with some published studies, our model 
provides a more specific and physiologically relevant evalua-
tion of the impact of pDCs in systemic autoimmunity.
In conclusion, we have identified pDCs to be a critical 
cell type responsible for the pathogenesis of lupus. We dem-
onstrate that the early activity of this cell type contributes to 
induce full disease symptoms via the activation of T cells, 
B cells, and cDCs. Our observation that the frequency of pDCs 
returns to normal in BXSB.DTR+ mice after DT treatment 
is stopped, yet protection from disease is sustained, implies 
that the pathogenic activity of pDCs is principally important 
during a limited window early in disease progression, at 
which time they are able to initiate the activation of other 
immune cell types. We cannot entirely dismiss a contribution 
of pDCs at later stages of disease; however, it is most likely 
that pDCs are less important once a threshold level of cell ac-
tivation has been achieved, as we see a significant delay in the 
progression of lupus after a limited period of pDC ablation. 
Our work suggests that transient short-term depletion of 
pDCs may represent an attractive therapeutic approach for 
the early treatment of lupus by inhibiting the activation of 
autoreactive T and B cells while leaving the antiviral re-










Published September 1, 2014
JEM Vol. 211, No. 10 
Article
1989
PCR System (Applied Biosystems) using TaqMan Fast Advanced Master 
Mix (Life Technologies) and the following gene expression assays (Life 
Technologies): IFI44 (Mm00505670_m1), MX1 (Mm00487796_m1), 
OAS3 (Mm00460944_m1), IRF7 (Mm00516793_g1), and 18S endogenous 
control (Mm03928990_g1). Amplification cycle data were captured and 
quantified using SDS 2.4 and RQ Manager 1.2.2 (Applied Biosystems), and 
fold changes were calculated compared with 18S endogenous control. Data 
were further analyzed using GraphPad Prism 6.
Statistical analysis. Significant differences between any two groups were 
calculated with Prism software (GraphPad Software, Inc.). Unless noted, 
statistical significance was assessed using the unpaired two-tailed Student’s 
t test with Welch’s correction applied where appropriate. The Mann-Whitney 
test was applied where indicated. P values <0.05 were considered signifi-
cant. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Absence of * indicates non-
significant differences.
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Antinuclear antibody assays. Serum samples were prepared by diluting in 
PBS. Diluted samples were applied to HEp-2 cell–coated slides (MBL Bion) 
and incubated 1 h at room temperature in a humidified chamber. Slides were 
washed 3 times in PBS. Bound antibodies were detected after incubation 
with Alexa Fluor 488-conjugated F(ab) goat anti–mouse IgG (Invitrogen) 
diluted 1:200 in PBS for 1 h at room temperature in a humidified chamber. 
Slides were washed 3 times (5 min each) in PBS and images were visualized 
on a Nikon Eclipse E800 microscope equipped with a 60×/1.4 numerical 
aperture oil objective. Images were captured using a Magnafire camera (Op-
tronics) and processed using Nikon Elements and ImageJ (National Institutes 
of Health) software. ANA titers are represented as highest dilution of serum 
that contained detectable autoantibodies. Additionally, serum autoantibodies 
were evaluated using the Autoantigen Microarray Panel I at the Genomics 
and Microarray Core Facility (University of Texas Southwestern, Dallas, 
TX). Subsequent analyses of normalized signals were completed using 
GraphPad prism 6.0. Fluorescence intensities in heat maps that were higher 
than the row mean were shown in red; those below than the row mean were 
shown in blue; those near the mean were shown in white.
Serum protein arrays. Murine serum samples were evaluated and quanti-
fied using the RodentMAP v.3.0 multi-analyte platform (Myriad RBM). 
Samples with undetectable protein were assigned values equivalent to the 
individual assay LLOQ. Heat maps were generated using GENE-E online 
software (http://www.broadinstitute.org/cancer/software/GENE-E/).
Tissue pathology and histological analysis. Kidneys were either fixed 
in 10% neutral buffered formalin and sections were stained for hematoxylin 
and eosin (H&E) and Periodic acid-Schiff (PAS) by the Anatomical and 
Molecular Pathology Laboratory at Washington University (St. Louis). Fixed 
sections were blindly scored on a scale of 0–3 for increasing severity of glo-
merulonephritis (GN) per the following scale: (1) minimal damage to glo-
merular basement membranes (GBM) and little to no cellular infiltrates; 
(2) intermediate degree of cellular infiltration with moderate damage to GBM; 
(3) extensive cellular infiltration and severe destruction of GBM, which may 
include presence of casts indicating proteinuria. For immunohistochemistry, 
kidneys were frozen in OCT compound and cryostat sections (5 µm in thick-
ness) were stained with CD3 (rabbit monoclonal, clone SP7, dilution 1:100; 
Thermo Fisher Scientific), CD11b (rat IgG2b, clone M1/70, dilution 1:100; 
BD), Gr-1 (rat IgG2b, clone RB6-8C5, dilution 1:100), and 440c (rat 
IgG2b, dilution 1:50). Reactivity was detected using EnVision Rabbit 
(Dako) or Rat-on-Mouse HRP-Polymer kit (Biocare Medical), followed by 
diaminobenzidine as chromogen and hematoxylin as counterstaining. For 
immunofluorescence, sections were stained with fluorescein-conjugated 
goat F(Ab’)2 Fragment to Mouse Complement C3 (dilution 1:800; MP Bio-
medical) and with a CyTM3-conjugated AffiniPure F(Ab’)2 Fragment Don-
key Anti–Mouse IgG (H+L) (dilution 1:800; Jackson ImmunoResearch 
Laboratories) and counterstained with DAPI. The density of T cells and my-
eloid cells infiltrating the kidney tissue was defined by automatic cell count-
ing on digitalized slides (Aperio Scanscope, Nuclear algorithm) obtained 
from sections immunostained with CD3 and CD11b.
Measurement of Proteinuria. Urine was collected 1–2 d before sacrifice 
and proteinuria quantified using Albustix strips (Bayer) and semiquantitative 
scores were assigned based on colorimetric scale. (0, negative to trace; 1, 
30 mg/ml; 2, 100 mg/ml; 3, 300 mg/ml; 4, ≥2,000 mg/ml).
RT-PCR. Spleen and kidney samples were flash frozen in liquid nitrogen 
and stored at –80°C. Whole blood was obtained by cardiac puncture and 
immediately transferred to RNeasy Protect Animal Blood tubes (QIAGEN). 
After 2 h at RT, blood was stored at –80°C. According to the manufactur-
er’s recommendation, RNA was extracted from blood using the RNeasy 
Animal Blood Protect kit (QIAGEN), whereas RNA was extracted from 
spleen and kidneys using the RNeasy Fibrous Tissue Mini kit (QIAGEN). 
cDNA was amplified using random primers and SuperScript III (Life Tech-
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